 MINNEAPOLIS, April 06, 2021 GLOBE NEWSWIRE -- Panbela Therapeutics, Inc. Nasdaq: PBLA, a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology ASCO Annual Meeting, which will be held virtually from June 4-8, 2021. 